Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

APROTININ FOR SYSTEM SUITABILITY CRS (2.7 MG)

APROTININ FOR SYSTEM SUITABILITY CRS (2.7 MG)

9087-70-1

DISCOVER
DOCETAXEL FOR SYSTEM SUITABILITY CRS (15 MG)

DOCETAXEL FOR SYSTEM SUITABILITY CRS (15 MG)

148408-66-6

DISCOVER
IRBESARTAN IMPURITY A CRS (15MG)

IRBESARTAN IMPURITY A CRS (15MG)

NA

DISCOVER
MACROGOL POLY(VINYL ALCOHOL) GRAFTED COPOLYMER CRS (400 MG)

MACROGOL POLY(VINYL ALCOHOL) GRAFTED COPOLYMER CRS (400 MG)

96734-39-3

DISCOVER
MELPHALAN HYDROCHLORIDE CRS (110 MG)

MELPHALAN HYDROCHLORIDE CRS (110 MG)

02/07/3223

DISCOVER
ENROFLOXACIN FOR SYSTEM SUITABILITY CRS (15 MG)

ENROFLOXACIN FOR SYSTEM SUITABILITY CRS (15 MG)

93106-60-6

DISCOVER
CARBASALATE IMPURITY B CRS (5MG)

CARBASALATE IMPURITY B CRS (5MG)

530-75-6

DISCOVER
MISOPROSTOL FOR SYSTEM SUITABILITY CRS (5 MG)

MISOPROSTOL FOR SYSTEM SUITABILITY CRS (5 MG)

59122-46-2

DISCOVER
URSODEOXYCHOLIC ACID FOR SYSTEM SUITABILITY CRS (1.26 MG)

URSODEOXYCHOLIC ACID FOR SYSTEM SUITABILITY CRS (1.26 MG)

128-13-2

DISCOVER
TETRANDRINE CRS (20 MG)

TETRANDRINE CRS (20 MG)

518-34-3

DISCOVER
IRBESARTAN CRS (60 MG)

IRBESARTAN CRS (60 MG)

138402-11-6

DISCOVER
PHENYTOIN FOR SYSTEM SUITABILITY CRS (20 MG)

PHENYTOIN FOR SYSTEM SUITABILITY CRS (20 MG)

57-41-0

DISCOVER